MVIR Stock Overview
A pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Medivir AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.96 |
| 52 Week High | SEK 8.25 |
| 52 Week Low | SEK 2.33 |
| Beta | -0.26 |
| 11 Month Change | 2.42% |
| 3 Month Change | -2.95% |
| 1 Year Change | -59.45% |
| 33 Year Change | -70.69% |
| 5 Year Change | -87.51% |
| Change since IPO | -97.77% |
Recent News & Updates
Shareholder Returns
| MVIR | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -0.7% | -5.4% | -4.2% |
| 1Y | -59.4% | 18.1% | 12.5% |
Return vs Industry: MVIR underperformed the Swedish Biotechs industry which returned 21% over the past year.
Return vs Market: MVIR underperformed the Swedish Market which returned 17% over the past year.
Price Volatility
| MVIR volatility | |
|---|---|
| MVIR Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: MVIR has not had significant price volatility in the past 3 months.
Volatility Over Time: MVIR's weekly volatility has decreased from 12% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 10 | Jens Lindberg | www.medivir.com |
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma.
Medivir AB (publ) Fundamentals Summary
| MVIR fundamental statistics | |
|---|---|
| Market cap | SEK 332.02m |
| Earnings (TTM) | -SEK 96.52m |
| Revenue (TTM) | SEK 7.73m |
42.9x
P/S Ratio-3.4x
P/E RatioIs MVIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MVIR income statement (TTM) | |
|---|---|
| Revenue | SEK 7.73m |
| Cost of Revenue | SEK 76.47m |
| Gross Profit | -SEK 68.73m |
| Other Expenses | SEK 27.79m |
| Earnings | -SEK 96.52m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.86 |
| Gross Margin | -888.81% |
| Net Profit Margin | -1,248.18% |
| Debt/Equity Ratio | 0% |
How did MVIR perform over the long term?
See historical performance and comparison